J Scott Wolchko Sells 34,156 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) Stock

Fate Therapeutics, Inc. (NASDAQ:FATE) CEO J Scott Wolchko sold 34,156 shares of the stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $46.86, for a total transaction of $1,600,550.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

J Scott Wolchko also recently made the following trade(s):

  • On Thursday, November 18th, J Scott Wolchko sold 20,000 shares of Fate Therapeutics stock. The stock was sold at an average price of $54.27, for a total transaction of $1,085,400.00.
  • On Thursday, October 21st, J Scott Wolchko sold 30,000 shares of Fate Therapeutics stock. The stock was sold at an average price of $60.22, for a total transaction of $1,806,600.00.

Shares of FATE opened at $43.28 on Friday. The business’s fifty day moving average price is $54.40 and its 200 day moving average price is $66.87. Fate Therapeutics, Inc. has a 12-month low of $40.33 and a 12-month high of $119.85. The stock has a market capitalization of $4.13 billion, a PE ratio of -20.42 and a beta of 1.46.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.13. Fate Therapeutics had a negative return on equity of 28.25% and a negative net margin of 359.66%. The firm had revenue of $14.23 million for the quarter, compared to analysts’ expectations of $8.67 million. During the same period last year, the business posted ($0.36) earnings per share. The firm’s revenue for the quarter was up 88.3% on a year-over-year basis. Sell-side analysts predict that Fate Therapeutics, Inc. will post -2.27 EPS for the current year.

Several analysts have issued reports on FATE shares. Wedbush raised shares of Fate Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $71.00 to $74.00 in a research report on Wednesday, December 15th. Citigroup raised shares of Fate Therapeutics from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $94.00 to $87.00 in a research report on Monday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $122.00 price objective on shares of Fate Therapeutics in a research report on Tuesday. SVB Leerink lowered their price objective on shares of Fate Therapeutics from $118.00 to $115.00 and set an “outperform” rating for the company in a research report on Monday, November 8th. Finally, Morgan Stanley lowered their price objective on shares of Fate Therapeutics from $74.00 to $62.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 15th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $106.47.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Fate Therapeutics by 1.3% in the second quarter. Vanguard Group Inc. now owns 7,570,681 shares of the biopharmaceutical company’s stock valued at $657,060,000 after buying an additional 95,144 shares during the last quarter. BlackRock Inc. lifted its stake in Fate Therapeutics by 1.5% in the third quarter. BlackRock Inc. now owns 6,695,546 shares of the biopharmaceutical company’s stock valued at $396,844,000 after buying an additional 99,586 shares during the last quarter. Johnson & Johnson bought a new stake in Fate Therapeutics in the third quarter valued at $200,277,000. Bellevue Group AG lifted its stake in Fate Therapeutics by 23.9% in the third quarter. Bellevue Group AG now owns 3,238,036 shares of the biopharmaceutical company’s stock valued at $191,918,000 after buying an additional 624,500 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its stake in Fate Therapeutics by 21.3% in the third quarter. Farallon Capital Management LLC now owns 2,311,398 shares of the biopharmaceutical company’s stock valued at $136,997,000 after buying an additional 406,398 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.

Featured Article: How is net asset value different from market price?

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.